-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 30, the application submitted by the drug Ming Juno for the listing of the Riquilensai injection (tentative) was accepted by CDE, which is the second domestic listing of CAR-T therapy after Fosun Kate Yijilirunrace.
drug-focused technology, co-founded in 2016 by the drug Mingcon d'Or and Juno of the United States. On June 9,
, the company had just completed a $100 million round B financing.
Ricky Lesa (development code: JWCAR029) is a CAR-T therapy that targets CD19.
currently has two CAR-T treatments available worldwide, Yescarta (Gilead/Fosun Kate) and Kymriah (Nova), all on CD19.
2019, Yescarta and Kymriah generated global sales of approximately $456 million and $278 million, respectively.
.